A prostatecancer vaccine that the US Food and Drug Administration rejected in2007 has now , making it the first cancer vaccine to do so, according to . Made by of Seattle, does not prevent or cure prostate cancer,which killed 27,000 men in the US last year. However, the therapy extended thelives of 512 people with aggressive prostate tumors by four months,compared with patients who did not receive it. Although modest, the latest result shows that harnessing the immune system is a viable way to fight cancer. Oncologist at the in Boston, said he expectssimilar approaches to other cancers, such as melanoma, kidney cancerand lymphoma, to be approved in five to 10 years and that tweaks toProvenge will see it further extend people's lives.
Check out our in the from our .
–Stayton Bonner